| Title | Organism | Platform | |
|---|---|---|---|
| 1 | PromoCell Cardiomyocyte, Line A (LPC-1001)_drug_Alendronate (ALE)_48 hours | ||
| 2 | PromoCell Cardiomyocyte, Line A (LPC-1001)_drug_Paroxetine (PAR)_48 hours | ||
| 3 | PromoCell Cardiomyocyte, Line A (LPC-1001)_drug_Sorafenib (SOR) and Ursodeoxycholic acid (URS)_48 hours | ||
| 4 | PromoCell Cardiomyocyte, Line A (LPC-1001)_drug_Sunitinib (SUN) and Alendronate (ALE)_48 hours | ||
| 5 | PromoCell Cardiomyocyte, Line A (LPC-1001)_drug_Sunitinib (SUN) and Domperidone (DOM)_48 hours | ||
| 6 | PromoCell Cardiomyocyte, Line A (LPC-1001)_drug_Sunitinib (SUN) and Paroxetine (PAR)_48 hours | ||
| 7 | PromoCell Cardiomyocyte, Line A (LPC-1001)_drug_Sunitinib (SUN) and Ursodeoxycholic acid (URS)_48 hours | ||
| 8 | PromoCell Cardiomyocyte, Line A (LPC-1001)_drug_Sunitinib (SUN)_48 hours | ||
| 9 | PromoCell Cardiomyocyte, Line A (LPC-1001)_drug_Trastuzumab (TRS) and Domperidone (DOM)_48 hours | ||
| 10 | PromoCell Cardiomyocyte, Line A (LPC-1001)_drug_Trastuzumab (TRS) and Loperamide (LOP)_48 hours | ||
| 11 | PromoCell Cardiomyocyte, Line A (LPC-1001)_drug_Trastuzumab (TRS) and Ursodeoxycholic acid (URS)_48 hours | ||
| 12 | PromoCell Cardiomyocyte, Line A (LPC-1001)_drug_Amiodarone (AMI)_48 hours | ||
| 13 | PromoCell Cardiomyocyte, Line A (LPC-1001)_drug_Trastuzumab (TRS)_48 hours | ||
| 14 | PromoCell Cardiomyocyte, Line A (LPC-1001)_drug_Afatinib (AFA)_48 hours | ||
| 15 | PromoCell Cardiomyocyte, Line A (LPC-1001)_drug_Bosutinib (BOS)_48 hours | ||
| 16 | PromoCell Cardiomyocyte, Line A (LPC-1001)_drug_Cefuroxime (CEF)_48 hours | ||
| 17 | PromoCell Cardiomyocyte, Line A (LPC-1001)_drug_Cytarabine (CYT)_48 hours | ||
| 18 | PromoCell Cardiomyocyte, Line A (LPC-1001)_drug_Dasatinib (DAS) and Cytarabine (CYT)_48 hours | ||
| 19 | PromoCell Cardiomyocyte, Line A (LPC-1001)_drug_Dasatinib (DAS) and Methotrexate (MTX)_48 hours | ||
| 20 | PromoCell Cardiomyocyte, Line A (LPC-1001)_drug_Dasatinib (DAS)_48 hours | ||
| 21 | PromoCell Cardiomyocyte, Line A (LPC-1001)_drug_Erlotinib (ERL) and Cefuroxime (CEF)_48 hours | ||
| 22 | PromoCell Cardiomyocyte, Line A (LPC-1001)_drug_Erlotinib (ERL)_48 hours | ||
| 23 | PromoCell Cardiomyocyte, Line A (LPC-1001)_drug_Diclofenac (DIC)_48 hours | ||
| 24 | PromoCell Cardiomyocyte, Line A (LPC-1001)_drug_Methotrexate (MTX)_48 hours | ||
| 25 | PromoCell Cardiomyocyte, Line A (LPC-1001)_drug_Pazopanib (PAZ)_48 hours | ||
| 26 | PromoCell Cardiomyocyte, Line A (LPC-1001)_drug_Ruxolitinib (RUX)_48 hours | ||
| 27 | PromoCell Cardiomyocyte, Line A (LPC-1001)_drug_Sorafenib (SOR) and Entecavir (ENT)_48 hours | ||
| 28 | PromoCell Cardiomyocyte, Line A (LPC-1001)_drug_Sorafenib (SOR) and Ursodeoxycholic acid (URS)_48 hours | ||
| 29 | PromoCell Cardiomyocyte, Line A (LPC-1001)_drug_Sorafenib (SOR)_48 hours | ||
| 30 | PromoCell Cardiomyocyte, Line A (LPC-1001)_drug_Sunitinib (SUN) and Prednisiolone (PRE)_48 hours | ||
| 31 | PromoCell Cardiomyocyte, Line A (LPC-1001)_drug_Trastuzumab (TRS)_48 hours | ||
| 32 | PromoCell Cardiomyocyte, Line A (LPC-1001)_drug_Vandetanib (VAN)_48 hours | ||
| 33 | PromoCell Cardiomyocyte, Line B (LPC-1001)_drug_Amiodarone (AMI)_48 hours | ||
| 34 | PromoCell Cardiomyocyte, Line A (LPC-1001)_drug_Domperidone (DOM)_48 hours | ||
| 35 | PromoCell Cardiomyocyte, Line B (LPC-1001)_drug_Flecainide (FLE)_48 hours | ||
| 36 | PromoCell Cardiomyocyte, Line B (LPC-1001)_drug_Milrinone (MIL)_48 hours | ||
| 37 | PromoCell Cardiomyocyte, Line B (LPC-1001)_drug_Bosutinib (BOS)_48 hours | ||
| 38 | PromoCell Cardiomyocyte, Line B (LPC-1001)_drug_Domperidone (DOM)_48 hours | ||
| 39 | PromoCell Cardiomyocyte, Line B (LPC-1001)_drug_Diethylpropion (DTP)_48 hours | ||
| 40 | PromoCell Cardiomyocyte, Line B (LPC-1001)_drug_Entecavir (ENT)_48 hours | ||
| 41 | PromoCell Cardiomyocyte, Line B (LPC-1001)_drug_Lapatinib (LAP) and Ursodeoxycholic acid (URS)_48 hours | ||
| 42 | PromoCell Cardiomyocyte, Line B (LPC-1001)_drug_Lapatinib (LAP)_48 hours | ||
| 43 | PromoCell Cardiomyocyte, Line B (LPC-1001)_drug_Sorafenib (SOR) and Diethylpropion (DTP)_48 hours | ||
| 44 | PromoCell Cardiomyocyte, Line B (LPC-1001)_drug_Sorafenib (SOR) and Entecavir (ENT)_48 hours | ||
| 45 | PromoCell Cardiomyocyte, Line A (LPC-1001)_drug_Diethylpropion (DTP)_48 hours | ||
| 46 | PromoCell Cardiomyocyte, Line B (LPC-1001)_drug_Sorafenib (SOR) and Ursodeoxycholic acid (URS)_48 hours | ||
| 47 | PromoCell Cardiomyocyte, Line B (LPC-1001)_drug_Sorafenib (SOR)_48 hours | ||
| 48 | PromoCell Cardiomyocyte, Line B (LPC-1001)_drug_Sunitinib (SUN) and Loperamide (LOP)_48 hours | ||
| 49 | PromoCell Cardiomyocyte, Line B (LPC-1001)_drug_Sunitinib (SUN) and Ursodeoxycholic acid (URS)_48 hours | ||
| 50 | PromoCell Cardiomyocyte, Line B (LPC-1001)_drug_Tofacitinib (TOF)_48 hours | ||
| 51 | PromoCell Cardiomyocyte, Line B (LPC-1001)_drug_Trastuzumab (TRS) and Domperidone (DOM)_48 hours | ||
| 52 | PromoCell Cardiomyocyte, Line B (LPC-1001)_drug_Trastuzumab (TRS) and Ursodeoxycholic acid (URS)_48 hours | ||
| 53 | PromoCell Cardiomyocyte, Line B (LPC-1001)_drug_Trastuzumab (TRS)_48 hours | ||
| 54 | PromoCell Cardiomyocyte, Line B (LPC-1001)_drug_Ursodeoxycholic acid (URS)_48 hours | ||
| 55 | PromoCell Cardiomyocyte, Line B (LPC-1001)_drug_Vandetanib (VAN)_48 hours | ||
| 56 | PromoCell Cardiomyocyte, Line A (LPC-1001)_drug_Entecavir (ENT)_48 hours | ||
| 57 | PromoCell Cardiomyocyte, Line D (LPC-1001)_drug_Flecainide (FLE)_48 hours | ||
| 58 | PromoCell Cardiomyocyte, Line D (LPC-1001)_drug_Trastuzumab (TRS) and Ursodeoxycholic acid (URS)_48 hours | ||
| 59 | PromoCell Cardiomyocyte, Line D (LPC-1001)_drug_Trastuzumab (TRS)_48 hours | ||
| 60 | PromoCell Cardiomyocyte, Line D (LPC-1001)_drug_Cyclosporine (CYC)_48 hours | ||
| 61 | PromoCell Cardiomyocyte, Line D (LPC-1001)_drug_Domperidone (DOM)_48 hours | ||
| 62 | PromoCell Cardiomyocyte, Line D (LPC-1001)_drug_Diethylpropion (DTP)_48 hours | ||
| 63 | PromoCell Cardiomyocyte, Line D (LPC-1001)_drug_Imatinib (IMA) and Cyclosporine (CYC)_48 hours | ||
| 64 | PromoCell Cardiomyocyte, Line D (LPC-1001)_drug_Lapatinib (LAP)_48 hours | ||
| 65 | PromoCell Cardiomyocyte, Line D (LPC-1001)_drug_Loperamide (LOP)_48 hours | ||
| 66 | PromoCell Cardiomyocyte, Line D (LPC-1001)_drug_Sorafenib (SOR) and Ursodeoxycholic acid (URS)_48 hours | ||
| 67 | PromoCell Cardiomyocyte, Line A (LPC-1001)_drug_Flecainide (FLE)_48 hours | ||
| 68 | PromoCell Cardiomyocyte, Line D (LPC-1001)_drug_Sunitinib (SUN) and Loperamide (LOP)_48 hours | ||
| 69 | PromoCell Cardiomyocyte, Line D (LPC-1001)_drug_Trastuzumab (TRS) and Domperidone (DOM)_48 hours | ||
| 70 | PromoCell Cardiomyocyte, Line D (LPC-1001)_drug_Trastuzumab (TRS) and Loperamide (LOP)_48 hours | ||
| 71 | PromoCell Cardiomyocyte, Line D (LPC-1001)_drug_Ursodeoxycholic acid (URS)_48 hours | ||
| 72 | PromoCell Cardiomyocyte, Line E (LPC-1001)_drug_Amiodarone (AMI)_48 hours | ||
| 73 | PromoCell Cardiomyocyte, Line E (LPC-1001)_drug_Flecainide (FLE)_48 hours | ||
| 74 | PromoCell Cardiomyocyte, Line E (LPC-1001)_drug_Milrinone (MIL)_48 hours | ||
| 75 | PromoCell Cardiomyocyte, Line E (LPC-1001)_drug_Sunitinib (SUN) and Ursodeoxycholic acid (URS)_48 hours | ||
| 76 | PromoCell Cardiomyocyte, Line A (LPC-1001)_drug_Imatinib (IMA)_48 hours | ||
| 77 | PromoCell Cardiomyocyte, Line A (LPC-1001)_drug_Loperamide (LOP)_48 hours |
Interactive 3D principal component analysis of gene signatures. You can rotate the visualization and mouse over the data points.
Hierarchical clustering of genes based on weights from the differential expression method.
Enrichr is a web tool that performs gene set enrichment analysis. To generate the hierarchical clusterings below, GEN3VA enriched each gene signature using Enrichr and then clustered the terms. Use the select button to change Enrichr's background library.
Hierarchical clustering of enriched terms from
L1000CDS2 is a web tool that queries the LINCS L1000 dataset to identify small molecules that can reverse or mimic the observed input expression pattern. To generate the hierarchical clustering below, GEN3VA enriched each gene signature using L1000CDS2 to generate a list of perturbations that either mimic (red) and reverse (blue) expression.
